Cipla Q4 Results: Profit jumps 30% YoY; declares dividend of ₹16

Cipla Q4 Results: Pharmaceuticals company Cipla on Tuesday, May 13, reported a 30.12 per cent year-on-year (YoY) rise in its Q4FY25 consolidated net profit to ₹1,221.84 crore compared to ₹939.04 crore in the corresponding quarter of the previous financial year.

Revenue from sales rose 8.5 per cent YoY to ₹6,597.72 crore from ₹6,082.37 crore in Q4FY24. The pharmaceuticals segment clocked a revenue of ₹6,503.63 crore in Q4FY25, up 8.5 per cent against ₹5,996.38 crore in Q4FY24. Revenue from new ventures increased 35.44 per cent YoY to ₹288.48 crore from ₹212.99 crore in the same quarter of FY24.

EBITDA for the quarter jumped 17 per cent YoY to ₹1,538 crore, while EBITDA margin increased 150 bps YoY to 22.8 per cent.

For FY25, the company's profit jumped 28 per cent YoY to ₹5,273 crore and revenue increased 8 per cent YoY to 27,548 crore.

"In FY25, we recorded a revenue growth of 8 per cent over last year with the EBITDA margin of 25.9 per cent, driven by mix and other operational efficiencies. Our One-India business grew at a healthy 7 per cent YoY," said Umang Vohra, MD and Global CEO, Cipla.

"Key therapies in branded prescription business continued to outpace the market growth, trade generics business growth trajectory is back on track, and anchor brands of consumer health business maintained leadership position," said Vohra.

Vohra pointed out that the US business posted an all-time high annual revenue of $934 million. In One Africa, the company recorded a solid growth of 12 per cent YoY in USD terms, powered by firm performance across key markets. Emerging Markets and Europe delivered a substantial revenue growth of 15 per cent YoY on the back of a deep market focus strategy.

"Going ahead, the focus will be on growing our key markets, further building our flagship brands, investing in future pipeline, as well as focusing on resolutions on the regulatory front,” said Vohra.

Cipla FY25 dividend

Meanwhile, the company announced a final dividend of ₹13 per equity share for FY25 and a special dividend of ₹3 per equity share on the occasion of completing 90 years of the company, taking the total dividend to ₹16 per equity share of face value of ₹2 each.

Disclaimer: This story is for educational purposes only. The views and recommendations above are those of individual analysts or broking companies, not Mint. We advise investors to check with certified experts before making any investment decisions, as market conditions can change rapidly, and circumstances may vary.